Zhang, M., Liu, L., Hu, Y., Wei, G., Fu, S., Feng, J., Hong, R., Zhang, A. H., Huang, H. (2025). Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma. Blood. https://doi.org/10.1182/blood-2025-1940